-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

642.O1.6 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Targeted Doublet Combinations

Symposia: Chronic Lymphocytic Leukemia: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Lymphoid Leukemias, Biological therapies, clinical trials, adult, CLL, elderly, Combination therapy, Clinical Research, Diseases, Therapies, Lymphoid Malignancies, Study Population, Human, Minimal Residual Disease
Saturday, December 10, 2022: 9:30 AM-11:00 AM
La Nouvelle Orleans Ballroom AB (Ernest N. Morial Convention Center)
Moderators:
Inhye E. Ahn, MD, Dana-Farber Cancer Institute and Lindsey Roeker, MD, Memorial Sloan Kettering Cancer Center
Disclosures:
Roeker: Beigene: Consultancy; Janssen: Consultancy; AbbVie: Consultancy, Divested equity in a private or publicly-traded company in the past 24 months; AstraZeneca: Consultancy; Loxo Oncology: Consultancy, Other: Travel support, Research Funding; Pharmacyclics: Consultancy; Pfizer: Consultancy, Research Funding; TG Therapeutics: Consultancy; Abbott Laboratories: Current equity holder in publicly-traded company; Aptose Biosciences: Research Funding; Ascentage: Consultancy; Qilu Puget Sound Biotherapeutics: Research Funding.
The session includes 6 oral abstracts reporting the efficacy and safety of targeted doublet combinations (ibrutinib plus venetoclax) in CLL.
9:30 AM

Talha Munir, MBBS, MRCP, FRCPath, PhD1,2,3*, Louise-Rae Cherrill4*, Nichola Webster5*, Surita Dalal, PhD6*, Rebecca H. Boucher, BSc, MSc, PhD4*, Chhaya Sankhalpara, BSc7*, Francesca Yates, PhD4*, Sonia Fox, BSc4*, Donald Macdonald, MBChB, MD, FRCP, PhD, FCRPath8*, Christopher Fegan9*, Alison McCaig, MBChB, FRCPath, PhD, MRCP10*, Anna Schuh, MD, PhD, FRCP, FRCPath11, Andrew Pettitt, PhD, FRCPath12*, John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci13, Piers E.M. Patten, FRCP, FRCPath, PhD14, Stephen Devereux, PhD, FRCP, FRCPath, MRCPath, MB BS14*, Adrian Bloor, PhD FRCP FRCPath15*, Christopher P Fox, PhD16, Francesco Forconi, MD, PhD17*, Andy C. Rawstron, PhD6* and Peter Hillmen18

1Department of Haematology, St James's University Hospital, Leeds, United Kingdom
2Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom
3Consultant Haematologist, St James's Hospital, Leeds, United Kingdom
4Cancer Research UK, Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom
5St. James’s University Hospital, Leeds, United Kingdom
6HMDS, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
7Cancer Research UK, Clinical Trials Unit, University of Birmingham, Birmingham, ENG, United Kingdom
8Imperial College Healthcare NHS Trust, London, United Kingdom
9University Hospital of Wales, Cardiff, United Kingdom
10The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
11Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
12Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom
13St Bartholomew's Hospital, London, United Kingdom
14King's College London and King's College Hospital NHS Foundation Trust, London, United Kingdom
15Haematology, The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom
16Nottingham University Hospitals NHS Trust, Nottingham, GBR
17University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
18Institute of Oncology, St. James's University Hospital, Leeds, United Kingdom

9:45 AM

John N. Allan1, Tanya Siddiqi, MD2*, Thomas J. Kipps, MD, PhD3, Bryone J. Kuss, MBBS, PhD, FRACP, FRCPA4*, Xavier C. Badoux, MBBS, FRACP, FRCPA5, Jacqueline C. Barrientos, MD, MS6*, Alessandra Tedeschi7*, Stephen Opat, FRACP, FRCPA, MBBS8*, Ian W. Flinn, MD PhD9, Eva Gonzalez Barca, MD, PhD10*, Ryan Jacobs, MD11*, Edith Szafer-Glusman, PhD12*, Cathy Zhou, MS12*, Anita Szoke, MD12*, William G. Wierda, MD, PhD13*, Paolo Ghia, MD, PhD14 and Constantine S. Tam15*

1Weill Cornell Medicine, New York, NY
2City of Hope National Medical Center, Duarte
3UC San Diego Moores Cancer Center, San Diego, CA
4Flinders University and Medical Center, Bedford Park, SA, Australia
5Ministry of Health, Kogarah, NSW, Australia
6Mount Sinai Comprehensive Cancer Center, Miami Beach, FL
7ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
8Monash University, Clayton, VIC, Australia
9Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN
10Universitat de Barcelona, Institut Catalá d’Oncologia Hospitalet, Barcelona, Spain
11Levine Cancer Institute, Charlotte, NC
12Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA
13Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
14Universita' Vita-Salute San Raffaele C.F. 97187560152, Milano, MI, Italy
15Peter MacCallum Cancer Centre, Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia

10:00 AM

Carsten U Niemann, MD1*, Talha Munir, MBBS, MRCP, FRCPath, PhD2*, Carol Moreno, MD, PhD3*, Carolyn Owen, MD4*, George A Follows, MD, PhD5*, Ohad Benjamini6*, Ann Janssens, MD, PhD7*, Mark-David Levin8, Anders Österborg9*, Tadeusz Robak10, Martin Šimkovič11*, Sergey Voloshin12*, Vladimir I. Vorobyev, MD13, Munci Yagci, MD14*, Loic Ysebaert, MD, PhD15*, Keqin Qi16*, Qianaya Qi17*, Lori Parisi17*, Srimathi Srinivasan18*, Natasha Schuier19*, Kurt Baeten20*, Angela Howes, BSc, PhD21, Donne Bennett Caces17* and Arnon P. Kater, MD, PhD22

1Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark
2Consultant Haematologist, St James's Hospital, Leeds, United Kingdom
3Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Josep Carreras Leukaemia Research Institute, Barcelona, Spain
4Tom Baker Cancer Centre, Calgary, Canada
5Addenbrookes Hospital, Cambridge, United Kingdom
6Sheba Medical Center, Ramat Gan, Israel
7UZ Leuven Gasthuisberg, LEUVEN, Belgium
8Department of Internal Medicine, Albert Schweitzer hospital, Dordrecht, Netherlands
9Karolinska University Hospital, Stockholm, Sweden
10Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
114th Department of Internal Medicine – Haematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Hradec Kralove, Czech Republic
12Russian Scientific and Research Institute of Hematology and Transfusiology, St Petersburg, Russian Federation
13Bone Marrow Transplant, Botkin Hospital, Moscow, Russia
14Gazi Universitesi Tip Fakultesi, Ankara, Turkey
15Hematology Department, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
16Janssen Research & Development, Titusville, NJ
17Janssen Research & Development, Raritan, NJ
18Oncology Translational Research, Janssen Research & Development, Lower Gwynedd Township, PA
19Janssen Research & Development, Dusseldorf, Germany
20Janssen Research & Development, Beerse, Belgium
21Janssen Research & Development, Raritan
22Academic Medical Center, Amsterdam Zuidoost, NH, Netherlands

10:15 AM

Talha Munir, MBBS, MRCP, FRCPath, PhD1,2,3*, Alexandra Pitchford4*, Adrian Bloor, PhD FRCP FRCPath5*, Andrew Pettitt, PhD, FRCPath6*, Piers E.M. Patten, FRCP, FRCPath, PhD7, Francesco Forconi, MD, PhD8*, Anna Schuh, MD, PhD, FRCP, FRCPath9, Christopher P Fox, PhD10, Simona Gatto11*, Ben Kennedy, MBChB, FRCP, FRCPath12*, John Gribben13*, Nicholas Pemberton14*, Oonagh Sheehy, MB BCh BAO, MRCP, FRCPath15*, Gavin Preston, MD16*, Dena Howard17*, Anna Hockaday4*, David Cairns, PhD18*, Sharon Jackson4*, Natasha Greatorex4*, Nichola McWhirter19*, Jane Shingles19*, Kate Cwynarski, MD20*, Shankara Paneesha, MD21, David Allsup22*, Andrew Rawstron, PhD23* and Peter Hillmen24,25

1Consultant Haematologist, St James's Hospital, Leeds, United Kingdom
2NCRI CLL Sub-group, Leeds, United Kingdom
3Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom
4Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, Leeds, United Kingdom
5Haematology, The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom
6University of Liverpool, Liverpool, United Kingdom
7Comprehensive Cancer Centre, King’s College London, London, United Kingdom
8School of Cancer Sciences, University of Southampton, Southampton, United Kingdom
9Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
10Nottingham University Hospitals NHS Trust, Nottingham, GBR
11Cardiff and Vale UHB, Cardiff, United Kingdom
12Leicester Royal Infirmary, Leicester, United Kingdom
13Barts and The London School of Medicine, London, GBR
14Worcestershire acute Hospital NHS Trust, Worchester, United Kingdom
15Belfast HSC Trust, Belfast, United Kingdom
16Department of Haematology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom
17Roche Products Limited, Welwyn Garden City, United Kingdom
18Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, ENG, United Kingdom
19Haematology malignancy and diagnostic service, Leeds, United Kingdom
20University College London Hospitals NHS Foundation Trust, London, United Kingdom
21Birmingham Heartlands Hospital, Birmingham, United Kingdom
22Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, Hull, ENG, United Kingdom
23HMDS, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
24Institute of Oncology, St. James's University Hospital, Leeds, United Kingdom
25Section of Experimental Haematology, University of Leeds, Leeds, United Kingdom

10:30 AM

Nitin Jain, MD1, Michael J. Keating, MBBS2, Philip A. Thompson, MBBS1, Alessandra Ferrajoli2, Jayastu Senapati, MD, MBBS, DM1*, Jan A. Burger, MD, PhD1, Gautam Borthakur, MD1, Koichi Takahashi, MD, PhD2, Zeev E. Estrov, MD1, Marina Konopleva, MD, PhD1, Koji Sasaki, MD1, Tapan M. Kadia, MD3, Naveen Pemmaraju, MD1, Naval Daver, MD1, Elias Jabbour, MD1, Courtney D. DiNardo, MD, MSCE1, Yesid Alvarado, MD1, Musa Yilmaz, MD1, Prithviraj Bose, MD4, Maro Ohanian, DO1*, Rashmi Kanagal-Shamanna, MD5, Keyur Patel, MD, PhD5*, Jeffrey L. Jorgensen, MD, PhD5*, Sa A Wang, MD5*, Sameh Nassar, MD6*, Naveen Garg, MD6*, Hyunsoo Hwang7*, Xuemei Wang, MS7*, Nichole Cruz, RN1*, Ana Ayala, RN2*, William Plunkett, PhD8, Hagop Kantarjian, MD9, Varsha Gandhi, PhD8 and William G. Wierda, MD, PhD1

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
3Department of Leukemia, MD Anderson Cancer Center, Houston, TX
4The University of Texas MD Anderson Cancer Center, Houston, TX
5Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
6Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX
7Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
8Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
9Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

10:45 AM

Philip A. Thompson, MBBS1, Michael J. Keating, MBBS1, Alessandra Ferrajoli1, Nitin Jain, MD2, Christine B. Peterson, PhD3*, Naveen Garg, MD4*, Ana Ayala, RN1*, Jon A Hernandez1*, Tapan M. Kadia, MD2, Prithviraj Bose, MD5, Naveen Pemmaraju, MD6, Nicholas Short, MD1 and William G. Wierda, MD, PhD7

1Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
2Department of Leukemia, MD Anderson Cancer Center, Houston, TX
3Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX
4Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX
5The University of Texas MD Anderson Cancer Center, Houston, TX
6Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
7The University of Texas M.D. Anderson Cancer Center, Houston, TX

*signifies non-member of ASH